ATTRibute-PN
Study

What is the purpose of the ATTRibute-PN study?

The goal of the ATTRibute-PN study is to find out whether the study drug is safe and effective for people with polyneuropathy associated with hereditary amyloidosis (ATTR-PN).

Who can join the study?

You may be able to join the study if you meet the following requirements:

• You are between 18 and 90 years old
• You have been diagnosed with hereditary transthyretin amyloidosis (ATTR)
• You are experiencing symptoms of polyneuropathy, like nerve pain, tingling, numbness, or muscle weakness

Other requirements will apply.

What will happen during the study?

The ATTRibute-PN study can last up to 60 months (5 years).

Before receiving any study drug or study related assessments, your eligibility for participation and consent to participate are required.

If you qualify and join the study, you will be required to take the study drug twice per day and attend study clinic visits.